HK1219906A1 - 藥物組合物 - Google Patents

藥物組合物

Info

Publication number
HK1219906A1
HK1219906A1 HK16108106.6A HK16108106A HK1219906A1 HK 1219906 A1 HK1219906 A1 HK 1219906A1 HK 16108106 A HK16108106 A HK 16108106A HK 1219906 A1 HK1219906 A1 HK 1219906A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
HK16108106.6A
Other languages
English (en)
Inventor
Volker Schulze
Michael Brning
Detlef Stckigt
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48569985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1219906(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of HK1219906A1 publication Critical patent/HK1219906A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
HK16108106.6A 2013-06-06 2016-07-12 藥物組合物 HK1219906A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13170754 2013-06-06
PCT/EP2014/061711 WO2014195408A1 (en) 2013-06-06 2014-06-05 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
HK1219906A1 true HK1219906A1 (zh) 2017-04-21

Family

ID=48569985

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108106.6A HK1219906A1 (zh) 2013-06-06 2016-07-12 藥物組合物

Country Status (35)

Country Link
US (1) US20160120854A1 (zh)
EP (1) EP3003381B1 (zh)
JP (1) JP2016523229A (zh)
KR (1) KR20160018513A (zh)
CN (1) CN105263526A (zh)
AP (1) AP2015008890A0 (zh)
AR (1) AR096469A1 (zh)
AU (1) AU2014276870A1 (zh)
BR (1) BR112015030292A2 (zh)
CA (1) CA2914439A1 (zh)
CL (1) CL2015003535A1 (zh)
CR (1) CR20150641U (zh)
CU (1) CU24283B1 (zh)
CY (1) CY1119666T1 (zh)
DK (1) DK3003381T3 (zh)
DO (1) DOP2015000295A (zh)
EA (1) EA201501177A1 (zh)
ES (1) ES2652149T3 (zh)
HK (1) HK1219906A1 (zh)
HR (1) HRP20171888T1 (zh)
HU (1) HUE034883T2 (zh)
LT (1) LT3003381T (zh)
MA (1) MA38642A1 (zh)
NI (1) NI201500172A (zh)
NO (1) NO3003381T3 (zh)
PE (1) PE20152028A1 (zh)
PH (1) PH12015502703A1 (zh)
PL (1) PL3003381T3 (zh)
PT (1) PT3003381T (zh)
RS (1) RS56666B1 (zh)
SG (1) SG11201509114TA (zh)
SI (1) SI3003381T1 (zh)
TN (1) TN2015000524A1 (zh)
UY (1) UY35600A (zh)
WO (1) WO2014195408A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033131T2 (en) * 2013-06-11 2017-11-28 Bayer Pharma AG Derivatives of substituted triazolopyridines
TW201800408A (zh) 2016-06-15 2018-01-01 拜耳製藥公司 Mps-1抑制劑

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030212102A1 (en) * 2001-06-12 2003-11-13 Koretke Todd W Novel solid dispersion compositions
CN101048140B (zh) * 2004-08-27 2013-06-19 拜尔保健公司 用于治疗癌症的药物组合物
CN101125124B (zh) * 2006-08-16 2011-04-20 沈阳药科大学 一种亲脂性药物固体分散体的制备方法
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
CN102512358B (zh) * 2011-12-16 2013-04-10 南京农业大学 家畜用利福昔明阴道栓剂及其制备方法
CN102626384A (zh) * 2012-04-12 2012-08-08 临沂大学 一种姜黄素混悬剂及其制备方法

Also Published As

Publication number Publication date
ES2652149T3 (es) 2018-01-31
CY1119666T1 (el) 2018-04-04
JP2016523229A (ja) 2016-08-08
NI201500172A (es) 2016-01-06
HRP20171888T1 (hr) 2018-01-12
EA201501177A1 (ru) 2016-06-30
CR20150641U (es) 2016-01-29
HUE034883T2 (hu) 2018-03-28
US20160120854A1 (en) 2016-05-05
NO3003381T3 (zh) 2018-02-10
CN105263526A (zh) 2016-01-20
PL3003381T3 (pl) 2018-02-28
WO2014195408A1 (en) 2014-12-11
TN2015000524A1 (en) 2017-04-06
MA38642A1 (fr) 2017-10-31
AU2014276870A1 (en) 2015-11-19
AR096469A1 (es) 2015-12-30
PT3003381T (pt) 2017-12-20
BR112015030292A2 (pt) 2017-07-25
CU20150170A7 (es) 2016-03-31
EP3003381B1 (en) 2017-09-13
SI3003381T1 (en) 2018-01-31
KR20160018513A (ko) 2016-02-17
PH12015502703A1 (en) 2016-03-14
LT3003381T (lt) 2017-12-27
DK3003381T3 (en) 2017-12-11
SG11201509114TA (en) 2015-12-30
CL2015003535A1 (es) 2016-07-08
DOP2015000295A (es) 2016-03-15
EP3003381A1 (en) 2016-04-13
PE20152028A1 (es) 2016-02-07
UY35600A (es) 2015-01-30
RS56666B1 (sr) 2018-03-30
AP2015008890A0 (en) 2015-11-30
CU24283B1 (es) 2017-11-07
CA2914439A1 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
IL288961A (en) Pharmaceutical preparations
LT3030262T (lt) Kombinuota farmacinė kompozicija
PL2943181T3 (pl) Kompozycje farmaceutyczne
GB201304662D0 (en) Compositions
PL3043778T3 (pl) Kompozycje farmaceutyczne zawierające refametinib
ZA201408333B (en) Pharmaceutical compositions
GB201313615D0 (en) Compositions
EP2990038A4 (en) SOLID PHARMACEUTICAL COMPOSITION
EP3003324A4 (en) Pharmaceutical compositions
SG11201601477VA (en) Pharmaceutical composition
SG11201509194SA (en) Radiomitigating pharmaceutical formulations
ZA201506637B (en) Micronized pharmaceutical compositions
ZA201601645B (en) Bendamustine pharmaceutical compositions
HRP20171888T1 (hr) Farmaceutski pripravci
HUP1300496A2 (hu) Stabil kombinációs gyógyszerkészítmény
HK1220143A1 (zh) 藥物組合物
GB201320962D0 (en) Compositions
GB201304699D0 (en) Pharmaceutical compositions
GB201320959D0 (en) Compositions
GB201321497D0 (en) Pharmaceutical compositions
GB201312851D0 (en) Pharmaceutical compositions
GB201304625D0 (en) New pharmaceutical composition
GB201312224D0 (en) Compositions
GB201304927D0 (en) Compositions